Latest Trials

Systemic therapy trial

CheckMate 914 : A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in...

This phase III trial is trying to determine whether the combination of two immunotherapy drugs (nivolumab and ipilimumab) is effective in preventing cancer recurrence in patients with renal cell carcinoma, who have had part or all of their kidney removed

Status : Recruiting

Systemic therapy trial

DREAMM 8 : A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and...

This phase III trial will evaluate the safety and effectiveness of a type of immunotherapy, given in combination with chemotherapy (Arm A) or a type of targeted therapy (Arm B), in patients with multiple myeloma who have got worse or not responded to earlier treatment

Status : Recruiting

Systemic therapy trial

HER2CLIMB-02 : Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With...

This phase III trial is trying to understand if adding a targeted therapy drug to a new type of chemotherapy will help patients with HER2-positive breast cancer that has spread to other parts of the body or is unable to be surgically removed

Status : Recruiting

Treatment trial

A Phase 1, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted...

This phase I trial is testing different doses (amounts) of a new targeted therapy in adults with HER2-positive cancer

Status : Recruiting

Systemic therapy trial

GeoMETry-III : A Phase III, Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib...

This phase III trial is trying to understand whether an oral targeted therapy (capmatinib) is able to control lung cancer better than standard chemotherapy (docetaxel) and is safe to use in patients with lung cancer

Status : Recruiting

Systemic therapy trial

MERMAID-2 : A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of...

This phase III trial is evaluating the safety and effectiveness of a targeted adjuvant therapy in patients with stage 2 or 3 non-small cell lung cancer who have had their cancer removed or treated with curative intent

Status : Recruiting

Systemic therapy trial

DREAMM 3 : A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single...

This phase III trial is comparing the safety and effectiveness of a single drug treatment (belantamab mafodotin or blenrep) and a chemotherapy (pomalidomide plus low dose dexamethasone) for the treatment of patients with relapsed or refractory multiple myeloma

Status : Recruiting

Systemic therapy trial

ENHANCE : A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination With...

This phase III trial is testing the addition of a targeted therapy drug to treatment for previously untreated patients with intermediate-very high risk myelodysplastic syndromes (MDS)

Status : Recruiting

Systemic therapy trial

An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability,...

This phase I trial is trying to understand how safe and tolerable a new intravenous cancer drug (RO7283420) is for the treatment of Acute Myeloid Leukaemia (AML)

Status : Recruiting

Systemic therapy trial

MERMAID-1 : A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine...

This phase III trial is trying to understand whether adding a form of targeted therapy to standard chemotherapy will improve overall survival for patients with non-small cell lung cancer

Status : Recruiting

 

Looking for a trial? Use the search functionality to find the trial you are finding.